Protalex, Inc.

Calculating rank

USPTO Granted Patents = 6

% Expired Patents = 83.3

EPO Patents = 3

Trademarks = 1

Forward Citations = 8

Loading Chart...

1 inventor (with patents filed for the assignee):

Paul T Mann (6 out of 10 patents)

6 patents: Sort by Forward Citations

1. 9370552 - Protein A compositions and methods of use (2016-06-21),

2. 8603486 - Protein A compositions and methods of use (2013-12-10),

3. 8168189 - Protein A compositions and methods of use (2012-05-01),

4. 7807170 - Protein A compositions and methods of use (2010-10-05),

5. 7425331 - Protein A methods of use (2008-09-16),

6. 7211258 - Protein A compositions and methods of use (2007-05-01),

Company Overview

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of autoimmune and inflammatory diseases. Their lead product candidate, PRTX-100, is aimed at addressing unmet medical needs in diseases such as rheumatoid arthritis and immune thrombocytopenia. Protalex is dedicated to advancing innovative treatments that improve the lives of patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

6 Patents

#10 in Summit, NJ

#1,676 in New Jersey

#45,030 in US

Summit, NJ, United States of America

Protalex, Inc.

Forward Citations = 8

1 inventor:

Paul T Mann (6 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Protalex, Inc.. Retrieved from https://idiyas.com/company/protalex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]